Italia markets close in 1 hour

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
74,15+0,35 (+0,47%)
Al 10:30AM EDT. Mercato aperto.

Yahoo Finanza Italia rimuoverà le nostre bacheche con le conversazioni il giorno 15 agosto. Grazie per essere un membro così fedele della nostra community di conversazioni di finanza!

Accedi per pubblicare un messaggio.
  • j
    james
    $SLS conversation
    Speaking of the $MRK expanded partnership and license, don’t forget $BMY. Mesohope article: ‘..results of this [gp-s opdivo] single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks. Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.’

    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    Dr. Zauderer The Mesothelioma Dept chair at Memorial Sloan Kettering is investigating Gps combined w Opdivo for refractory patients, who have exhausted all options. Gps + Opdivo safety has been established, with no grade 3/4 and very few side effects beyond standard vaccination related symptoms.
    No brainer BMY is interested in combining Opdivo a CP Inhibitor, that removes the immune systems' brakes with Gps, the most effective t cell generation agent for 20 WT1 cancers. Gps has demonstrated broad spectrum epitope spread with B Cell cd3 Memory T cells, the hall mark of an effective long term, durable survival extension, in every trial.

    Therapy benefits of 10.5 months / 45.5 weeks vs 22* currently. Gps is already extending os rates nearly 5 months for sicker patients than what Opdivo + Yervoy was approved for in healthier patients.
    - Opdivo Yervoy recently Fda approved after extending survival 4 months for these patients in the front line setting.

    https://www.fiercepharma.com/pharma/wclc-bms-opdivo-yervoy-duo-slashes-mesothelioma-death-risk-by-26
    ". helping them live a median four months longer than those in the study’s chemo arm."

    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

    Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.
  • j
    james
    $SLS conversation
    Speaking of the $MRK expanded partnership and license, don’t forget $BMY. Mesohope article: ‘..results of this [gp-s opdivo] single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks. Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.’

    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    Dr. Zauderer The Mesothelioma Dept chair at Memorial Sloan Kettering is investigating Gps combined w Opdivo for refractory patients, who have exhausted all options. Gps + Opdivo safety has been established, with no grade 3/4 and very few side effects beyond standard vaccination related symptoms.
    No brainer BMY is interested in combining Opdivo a CP Inhibitor, that removes the immune systems' brakes with Gps, the most effective t cell generation agent for 20 WT1 cancers. Gps has demonstrated broad spectrum epitope spread with B Cell cd3 Memory T cells, the hall mark of an effective long term, durable survival extension, in every trial.

    Therapy benefits of 10.5 months / 45.5 weeks vs 22* currently. Gps is already extending os rates nearly 5 months for sicker patients than what Opdivo + Yervoy was approved for in healthier patients.
    - Opdivo Yervoy recently Fda approved after extending survival 4 months for these patients in the front line setting.

    https://www.fiercepharma.com/pharma/wclc-bms-opdivo-yervoy-duo-slashes-mesothelioma-death-risk-by-26
    ". helping them live a median four months longer than those in the study’s chemo arm."

    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

    Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    www.fiercepharma.com
  • C
    Cured
    $SLS conversation
    Simple investment thesis: Super low float, cash for almost 2 years, more coming + 3 Trial studies to report in the next quarter $MRK $BMY CDK9, along with an AML FDA Green light in Q1/2, by all accounts worth billions.

    Upcoming News:
    Now that the REGAL Phase 3 is in the Home stretch, a mere ReIteration of the Phase 3 Results Timeline will launch this baby bio.

    Seriously, is a quarter or 2 a long time to wait for a 2,500% Return on an Investment?

    MD Andersons Leukemia depart chairman running the Ph 3, who sees all the open label trial results, requesting Expanded Access, confirms 2 things; 1. Gps is doing what it has done in every trial, cure patients and extend survival well beyond existing treatment, and 2. Guarantees Immediate off-label prescription and ultimate FDA Approved Expanded label to Cr1 / PostASCT which is 5x the $200M Cr2 initial niche revenue projected by CF.

    95% of drugs w EAP’s get FDA approved.

    Hello!
  • L
    Larry
    $CLVS conversation
    CLVS

    Apparently deal is not done,in a good way. Worth noting Novartis who has eyes for not only FAP2286 in which they already hold rights for "LuMeir" but also highly valued PARAB C inhibitor.

    $NVS & $BMY have ER week of 7/27th, and $CLVS has. Board meeting that same week.

    From Samos group on Twitter
  • C
    Cured
    $SLS conversation
    $BMY would pay billions for GPs - just for the Meso data: The treatment, called galinpepimut-S, was part of a study involving eight patients with stage 2, stage 3, or stage 4 pleural mesothelioma. All patients had either relapsed after standard treatment (chemotherapy or immunotherapy) or were unresponsive to standard treatment. These cases usually don’t survive for more than a few months due to how fast mesothelioma spreads.

    The study paired galinpepimut-S with Opdivo, the brand name for the immunotherapy drug nivolumab. Opdivo and Yervoy (ipilimumab) are approved for pleural mesothelioma as immunotherapy drugs. Seven of eight patients received at least three doses of galinpepimut-S, and the last dose also included Opdivo.

    The eight patients had a median survival of 9.4 months, which is better than usual for patients after a relapse of mesothelioma. The seven patients who had galinpepimut-S and Opdivo survived for an average of 10.5 months.

    https://www.mesotheliomaguide.com/community/immunotherapy-drug-galinpepimut-s-for-mesothelioma/
  • C
    Cured
    $SLS conversation
    $bmy (or any CPI Pharma ) will Pay billions for Gps Mesothelioma license rights [Gps Opdivo Patients median Os of 10.5 months And COUNTING] By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
    https://www.asbestos.com/news/2022/06/14/novel-clinical-trial-helping-late-stage-mesothelioma-patients/
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    www.asbestos.com
  • L
    Larry
    $CLVS conversation
    Samos Group @SamosGroup • 10h
    §CLVS Rumors & rumblings as of last night that - deal is done, it is $BMY. No other details outside of $SNY did not counter and announcement can be made anytime. I'd inquire with IR this weekend and Monday regarding the strategic alternatives they referenced in latest 14A.
  • A
    A
    $CLVS conversation
    Curious $BMY Job posting in Broomfield, CO.

    I don't see any BMS R&D sites in CO or at least in Broomfield currenty listed on their website. Regardless, those are interesting responsibilities considering the current $CLVS merger rumors.
    From Samos group on Twitter
  • C
    Cured
    $SLS conversation
    3 ongoing, active Immunotherapy Trials in End stage, platinum resistant/refractory;
    1. In combination w $MRK Keytruda in Ovarian Cancer and
    2. in combination $BMY w Opdivo in Mesothelioma and also 3. a nearly complete Phase 3 trial to extend and prolong remission for patients in Secondary AML Remission.

    3D Med currently initiating 5 Gps trials in Greater china, as a monotherapy and in combination w Envafolimub, the first injectable Checkpoint inhibitor.

    Current Status: for 2.
    GPs Opdivo combination for end stage Mesothelioma patients; 10.5 months of median survival reported in June vs 22 weeks w current standard of care. Gps Opdivo median os has not yet been reached as more than half the patients continue to survive.
    This data is already causing great excitement within the community
    https://www.asbestos.com/news/2022/06/14/novel-clinical-trial-helping-late-stage-mesothelioma-patients/
    Google Galinpepimut-S and Opdivo for several others.

    While it's relatively easy, in the short run to manipulate the SLS share price in the long run, the true value will be realized. And it's significant, not just for SLS but Mrk BMY and many other big pharma developing Check point inhibitors.
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    Late-stage patients with pleural mesothelioma have survived longer than anticipated in a phase I clinical trial studying a novel combination treatment.
    www.asbestos.com
  • A
    A.I.R.
    Plieth:

    Given Revlimid Q2 sales -22% on generics it's prob not too surprising to see $BMY touting iberdomide, which recently entered phase 3

    Me;

    These BP companies will need a new antibody
  • P
    P509$
    $SLS conversation
    $BMY is sizing up a Mesothelioma market value of $3- $4 B or $150 $200 Per share
  • C
    Cured
    $SLS conversation
    I expect a significant Upfront Money with the New $BMY partnerhsip: Gps Opdivo just more than doubled survival for mesothelioma patients. "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
  • C
    Cured
    $SLS conversation
    $mrk or $bmy are Going to buy this.
    Be Holding
  • C
    Cured
    $XBI conversation
    $bmy growing revenue: Opdivo combination w Gps $sls “Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences (NASDAQ:SLS) recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo.”
  • C
    Cured
    $SLS conversation
    This is the latest from Angelo on Ovarian Cancer Data (Keytruda $MRK + GPS)
    'I am excited to share our top-line data from our combination study of GPS with the checkpoint inhibitor pembrolizumab in patients diagnosed with WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer. With 43.1 weeks of follow-up, the median overall survival among the patients in this trial has not yet been reached and the median progression-free survival was 12 weeks. This compares favorably to 8.4 weeks for pembrolizumab alone seen in a similar platinum-resistant ovarian cancer patient population in the KEYNOTE-100 study - a 43 percent increase in the GPS combination with pembrolizumab. The disease control rate was 53.9 percent – in comparison, in the KEYNOTE-100 study, the observed disease control rate was 37.2% - a 45% increase in the GPS combination with pembrolizumab.

    In this exceedingly difficult to treat patient population with active disease, the combination of GPS and pembrolizumab seems to be effective at halting or slowing down progression. GPS has typically been utilized in the remission setting and to see such intriguing data in combination with pembrolizumab in active disease is indeed exciting. I would like to wholeheartedly thank all patients for participating in the study as well as their physicians, nurses, and study teams as well as our teams at SELLAS and Merck.'

    As a note: The median overall survival is the time — expressed in months or years — when half the patients are expected to be alive. In our case it means that after 43 weeks (around > 10 months) we still have more than 50% (in a range that goes from 51 to 100%) of the patients alive, thus the median overall survival has not been reached: good stuff...

    Its either $mrk or $BMY
  • C
    Cured
    $SLS conversation
    - Expect Upfront Money w a New $BMY partnerhsip: Gps Opdivo just more than doubled survival for mesothelioma patients.
  • C
    Cured
    $SLS conversation
    The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released. . results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. (Gps $BMY Opdivo) By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.
  • C
    Cured
    $SLS conversation
    Half the patients remain - Gps + Opdivo + Yervoy will become the SOC. $1B $BMY License for these rights
    "results of this single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks.

    Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.
  • J
    Joe
    $SLS conversation
    This from the article that Says $BMY will be Generating Future Revenue Using GPS in combination with Opdivo for Meso Patients “Opdivo is continuing to grow sales too, and it is reasonably probable that multiple combination therapies will be tested and approved in the coming years. For example, SELLAS Life Sciences (NASDAQ:SLS) recently reported updated data from a phase 1 trial of its galinpepimut-S drug in combination with BMY's Opdivo.

    The data suggested and increased survival rate in patients with malignant pleural mesothelioma ("MPM") who either relapsed or were resistant to treatment after at least one line of standard of care chemotherapy. "This updated data is very encouraging, as it not only confirms our data reported in June 2021, but now reflects an increased survival benefit even though almost all additionally enrolled patients had Grade III and IV malignant mesothelioma," commented SELLAS President and CEO Angelos Stergiou.
  • D
    Dude
    $SLS conversation
    Gps was included as future Revenue Generator for $BMY? SlS shares are a steal. $mrk bmy bidding war.
    https://seekingalpha.com/article/4520830-bristol-myers-is-melting-up-again